Back

NovoBioJect raises active methotrexate levels 38% in rheumatoid arthritis study

Verifying
  • Amplio Pharma reported positive Phase 1b biomarker results for NovoBioJect in rheumatoid arthritis patients.
  • NovoBioJect increased intracellular MTX-PG4 and MTX-PG5 accumulation by 38%, with P = 0.009.
  • Amplio plans a Dutch Phase 2a study and is initiating approximately €10 million in Series A financing.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.